生物分析市場中的實驗室自動化 - COVID-19 的增長、趨勢、影響和預測（2022-2027 年）

在預測期內，生物分析市場的實驗室自動化預計將以 6.1% 的複合年增長率增長。

生物技術公司和研究機構大量投資於研發活動，主要是為了開發可能增強其產品的新技術。這些公司正在蛋白質組學、藥物測試、高通量篩選和組合化學方面進行投資，以開發環保生物技術試劑。因此，預計此類新興市場的發展將有助於預測期內市場的增長。

主要亮點

• 多年來，實驗室自動化已經改變了藥物發現領域，主要是由於兩個主要影響因素：減少錯誤和成本效益。此外，自動化通過促進化合物收集改變了傳統的藥物發現過程，使生物技術革命和眾多組合技術能夠識別許多目標。
• 市場生態系統中的供應商專注於有機和無機增長戰略，以保持市場競爭力。例如，Agilent Technologies開發了 Seahorse XF HS 迷你分析儀，這是 Seahorse XF 平台的最新版本，可提供最佳的 Seahorse XF 數據質量、工作流程和用戶體驗。細胞代謝是影響細胞命運、功能和強度的主要因素。
• 此外，根據 ClinicalTrials.gov 的數據，截至 2022 年 3 月，共有 409,300 項臨床試驗註冊。隨著對研究和開發的日益關注，預計將越來越需要加強世界各地研究實驗室的能力。
• COVID-19 的爆發提高了對病毒檢測、跟蹤和追蹤的要求，而診斷實驗室需要具備每天檢測多達數千個樣本的能力，這推動了所研究市場的增長。由於實驗室自動化程度的提高，預計生物分析市場將顯著增加。

主要市場趨勢

血液分析儀領域的顯著增長

• 自動化分析儀可以高效、快速地測量多種生物樣品中的各種化學物質和其他特性，而無需人工協助。使用自動分析儀比手動分析化學反應更方便。使用控制系統和各種程序來分析化學反應。此外，自動化技術可以節省時間。
• 血液分析儀包含多個分析模塊，具有自己的樣品製備過程。它用於診斷許多疾病，包括感染、貧血、病毒、糖尿病、遺傳問題和癌症。此外，可以調整治療藥物和非法藥物的血漿藥物濃度。
• 許多市場供應商都在戰略性地投資於研發，以將新產品推向市場。例如，2022年3月，邁瑞推出了BC-700系列血液分析儀，結合了紅細胞沉降率（ESR）檢測和全血細胞計數（CBC）。此外，該系列還包括 BC-760/BC-780 兩種自動上樣器型號和 BC-700/BC-720 兩種開瓶型號。
• 同樣，2022 年 4 月，Sysmex Europe 推出了流式細胞儀 XF-1600，獲得了 CE 標誌（表明符合歐洲 IVD 法規和 IVD 應用）。它是一款 10 色分析儀，專為高效可靠的免疫表型數據收集而設計。通過這種方式，新產品的推出旨在為供應商擴大銷售機會。
• 此外，自動血細胞計數器通過對全血中的成分進行定性分析來幫助診斷瘧疾。該分析基於對含有 DNA 並感染瘧原蟲的紅細胞計數。2020 年 7 月，儘管受到 COVID-19 的影響，Sysmex 的自動血細胞計數器 XN-31 獲得了國內銷售批准，從而在日本實現了瘧疾的體外診斷。

北美擁有最大的市場份額

• 該地區臨床和臨床前試驗數量的增加增加了對快速樣品分析的需求，使自動化成為促進市場增長的關鍵因素之一。例如，根據世界衛生組織（WHO）的數據，美國在 1999 年至 2021 年間註冊的臨床試驗總數最高（157,618），其次是中國和日本。
• 美國政府和 FDA 的嚴格監管，診斷市場需求的增加，以及由於該地區心血管和神經系統疾病等各種疾病的增加而增加的發現和實驗室的利用率，推動了市場的增長。我在這裡.美國主導著北美市場，是該地區的主要收入來源。
• 多年來，美國一直是臨床研究的先驅。該國是Pfizer, Novartis, GlaxoSmithKline, J&J, 和Novartis等主要製藥公司的所在地。該國還擁有最大的合同研究組織 (CRO)。該國主要的 CRO 包括美國實驗室公司控股公司、IQVIA、Syneos Health 和 Parexel International Corp.。
• 此外，許多主要供應商繼續投資以擴大其在該地區的足跡，這推動了市場的增長。例如，2021 年 9 月，Thermo Fisher Scientific Inc.宣布計劃投資 1.54 億美元並創造 290 個額外工作崗位，以擴大其在北卡羅來納州皮特縣的業務。
• 該地區的產品創新也在繼續增長。例如，2021 年 10 月，Sysmex America 發布了 XN-30 僅供研究使用 (RUO) 自動血液分析儀，這是第一款用於瘧疾檢測的自動血液分析儀。

競爭格局

生物分析中的實驗室自動化市場得到鞏固。主要參與者擁有最大的市場份額。此外，基於產品創新和技術進步等因素，生物分析實驗室自動化市場的參與者越來越多地相互競爭。

• 2022 年 5 月 - Thermo Fisher Scientific 推出了自動 Indigo 臨床化學分析儀，可在樣本驅動測試中快速獲得結果。它適用於小樣本量並使用更少的水，使您的實驗室運行更具成本效益。
• 2021 年 2 月 - Beckman Coulter 宣布推出 DxH 560 AL，這是一款台式血液分析儀，旨在緩解中小型實驗室面臨的時間和資源限制。自動加載、閉管抽吸和無人值守功能允許用戶連續添加多達 50 個樣本，提供針對血源性病原體的安全性並減少手動儀器工作。

其他福利

• Excel 格式的市場預測 (ME) 表
• 3 個月的分析師支持

目錄

第 1 章 簡介

• 研究假設和市場定義
• 調查範圍

第二章研究方法論

第三章執行摘要

第四章市場洞察

• 市場概況
• 產業吸引力——波特五力分析
  • 供應商的議價能力
  • 買方議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 競爭對手之間的競爭
• 行業價值鏈分析
• 評估 COVID-19 對行業的影響

第五章市場動態

• 市場驅動力
  • 對個性化醫療的需求不斷增長
  • 通過技術創新改進解決方案
• 市場製約因素
  • 設置資金要求高
• 市場技術快照（人工智能等尖端技術的影響）

第六章市場細分

• 通過提供
  • 設備
    • 自動液體處理器
    • 自動盤子處理器
    • 機械臂
    • AS/RS
    • 視覺系統
  • 軟件
• 按分析儀類型
  • 生化分析儀
  • 免疫系統分析儀
  • 血液分析儀
  • 細胞計數器
  • 凝血測量儀
• 按地區列出
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第 7 章 競爭格局

• 公司簡介
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies
  • Hamilton Company
  • Siemens Healthineers AG
  • Becton Dickinson & Co.
  • Hudson Robotics Inc.
  • Beckman Coulter Inc.（Danaher Corporation）
  • Tecan Genomics Inc.
  • Shimadzu Corporation

第八章投資分析

第九章 市場潛力

Lab automation in bioanalysis market is expected to grow at a CAGR of 6.1% over the forecast period. Biotechnology companies and research organizations have been investing massive amounts in R&D activities, primarily to develop new technologies that are expected to enhance their products. These companies are investing in proteomics, drug testing, high-throughput screening, and combinational chemistry to develop an environment-friendly biotechnology reagent. Hence, such developments are expected to contribute to the growth of the market over the forecast period.

Key Highlights

• Laboratory automation transformed the realm of drug discovery over the years, primarily through two major influential factors, such as error reduction and cost-benefit. Additionally, automation transformed the traditional drug discovery process by making it feasible to identify many targets through the biotechnology revolution and numerous combinatorial technologies, which fueled compound collection.
• Vendors present in the market ecosystem focus on organic & inorganic growth strategies to stay competitive in the market. For example, Agilent Technologies has developed Seahorse XF HS Mini Analyzer, the newest addition to the Seahorse XF platform that delivers the best in Seahorse XF data quality, workflow, and user experience. Cell metabolism is a major driver of cell fate, function, and fitness.
• Moreover, according to ClinalTrials.gov, the total number of registered clinical studies as of March 2022 was 409,300. Such increased focus on research and development is expected to drive the need for enhancing laboratory capabilities across the world.
• With the outbreak of COVID-19, the lab automation in bioanalysis market will witness a significant increase in demand due to the increasing requirement for testing, tracing, and tracking of the virus and the fact that the diagnostic lab needs many capabilities to test up to thousands of samples per day is driving the lab automation in the market studied.

Key Market Trends

Hematology Analyzers Segment to Grow at a Significant Rate

• An automated analyzer, with minimal human assistance, measures various chemicals and other characteristics in several biological samples, both efficiently and quickly. The use of automated analyzers is more convenient, as compared to the manual analysis of chemical reactions. It uses control systems and different programs to analyze chemical reactions. Furthermore, it saves time due to the automation technique.
• Hematology analyzers include multiple analytical modules with unique sample preparation processes. They are used in the diagnosis of various diseases, such as infections, anemia, viruses, diabetes, genetic problems, and cancer. Moreover, they regulate the plasma drug level for both therapeutic and illicit drugs.
• Many of the market vendors are strategically investing in research and development and are introducing new products in the market. For instance, in March 2022, Mindray launched BC-700 Series, a hematology analyzer series that incorporates both the erythrocyte sedimentation rate (ESR) tests and Complete Blood Count (CBC). In addition, the series includes two autoloader models, such as the BC-760/BC-780, and two open vial models, such as the BC-700/BC-720, that are designed to empower medium-volume laboratories with advanced technologies.
• Similarly, in April 2022, Sysmex Europe launched the Flow Cytrometer XF-1600 with CE marking (indicating compliance with European IVD Regulation and IVD use). The product is a 10-color analyzer designed for highly efficient and reliable data collection in immunophenotyping. Thus, the launch of new products is driving more sales opportunities for the vendor.
• Further, the automated hematology analyzer helps diagnose malaria by conducting qualitative analyses of formed elements in whole blood. The analysis is based on counting DNA-containing, malaria-infected red blood cells that have malaria parasites. In July 2020, despite the impact of COVID-19, Sysmex received marketing approval in Japan for its Automated Hematology Analyzer XN-31, making it available for the in-vitro diagnosis of malaria in the country.

North America to Hold Largest Market Share

• A rise in the number of clinical and pre-clinical studies in the region has made the need for speedy analysis of samples imperative, making automation one of the key components contributing to the growth of the market. For instance, as per the World Health Organization, the United States had the highest total number of trials registered during 1999-2021 (157,618), followed by China and Japan.
• Strict regulations by the US government and the FDA, the growing demand in the diagnostic market, and the increasing usage of discovery and research labs, owing to the rising presence of various diseases, such as cardiovascular diseases and neurological diseases in the region, have fueled the growth of the market. The US dominates the North American market and is the major revenue contributor in the region.
• The United States has been a pioneer in clinical research for years. This country is home to some of the major pharmaceutical companies, like Pfizer, Novartis, GlaxoSmithKline, J&J, and Novartis. The country also has the highest concentration of contract research organizations (CROs). Some of the major CROs in the country are Laboratory Corp. of America Holdings, IQVIA, Syneos Health, and Parexel International Corp.
• Further, many major vendors continue to invest in expanding their footprint across the region, which is aiding the market growth. For instance, in September 2021, Thermo Fisher Scientific Inc. announced plans to invest USD 154 million and create 290 additional jobs with an expansion of its Pitt County, NC operations.
• Product innovation also continues to rise in the region. For instance, in October 2021, Sysmex America introduced the XN-30 Research Use Only (RUO) Automated Hematology Analyzer, the first automated hematology analyzer for malaria detection.

Competitive Landscape

The lab automation in bioanalysis market is consolidated. Major players have the maximum market share. Also, the players in the lab automation in bioanalysis market are increasingly competing against each other based on factors such as product innovations and technological advances.

• May 2022 - Thermo Fisher Scientific introduced the Automated Indiko Clinical Chemistry analyzer, which produces results quickly with sample-oriented testing. It can operate with low sample volumes and uses small amounts of water which enables running the laboratory more cost-efficiently.
• February 2021 - Beckman Coulter announced the launch of the DxH 560 AL, a tabletop hematology analyzer designed to reduce the time and resource constraints faced by small- to mid-sized laboratories. With its auto-loading functionality, closed tube aspiration, and walk away capabilities, users can continually add up to 50 samples, provide safety against blood-borne pathogens and spend less time on manual instrument tasks.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumption and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHTS

• 4.1 Market Overview
• 4.2 Industry Attractiveness - Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Threat of Substitutes
  • 4.2.5 Intensity of Competitive Rivalry
• 4.3 Industry Value Chain Analysis
• 4.4 Assessment of Impact of Covid-19 on the Industry

5 MARKET DYNAMICS

• 5.1 Market Drivers
  • 5.1.1 Rising Demand for Personalized Medicines
  • 5.1.2 Technological Innovations Resulting in Improved Solutions
• 5.2 Market Restraints
  • 5.2.1 High Capital Requirements for Setup
• 5.3 Technology Snapshot of the Market (Effect of AI and other Cutting-edge Technologies)

6 MARKET SEGMENTATION

• 6.1 By Offering
  • 6.1.1 Equipment
    • 6.1.1.1 Automated Liquid Handlers
    • 6.1.1.2 Automated Plate Handlers
    • 6.1.1.3 Robotic Arms
    • 6.1.1.4 AS/RS
    • 6.1.1.5 Vision Systems
  • 6.1.2 Software
• 6.2 By Type of Analyzers
  • 6.2.1 Biochemistry Analyzers
  • 6.2.2 Immuno-Based Analyzers
  • 6.2.3 Hematology Analyzers
  • 6.2.4 Cell Counters
  • 6.2.5 Coagulometers
• 6.3 By Geography
  • 6.3.1 North America
  • 6.3.2 Europe
  • 6.3.3 Asia-Pacific
  • 6.3.4 Latin America
  • 6.3.5 Middle East and Africa

7 COMPETITIVE LANDSCAPE

• 7.1 Company Profiles
  • 7.1.1 Thermo Fisher Scientific Inc.
  • 7.1.2 Agilent Technologies
  • 7.1.3 Hamilton Company
  • 7.1.4 Siemens Healthineers AG
  • 7.1.5 Becton Dickinson & Co.
  • 7.1.6 Hudson Robotics Inc.
  • 7.1.7 Beckman Coulter Inc. (Danaher Corporation)
  • 7.1.8 Tecan Genomics Inc.
  • 7.1.9 Shimadzu Corporation

8 INVESTMENT ANALYSIS

9 FUTURE OF THE MARKET